Nebraska is receiving $260,077 from a multi-state settlement.
Bristol-Myers Squibb reached a settlement with 43 states, including Nebraska, over how it marketed one of its drugs.
A news release from the Nebraska attorney general’s office alleges the company engaged in unfair or deceptive trade practices.
The complaint focuses on the drug Abilify, which the FDA approved for the treatment of schizophrenia in 2002.
Since then, the government allowed several other uses, but not for elderly patients with symptoms of dementia and Alzheimer’s disease.
The complaint also alleges Bristol-Myers Squibb marketed Abilify for use in children, which the FDA also had not approved.
Overall, the company is paying out $19.5 million to settle the matter.